Frontiers in Clinical Drug Research - Anti infectives is a book series that brings updated reviews to readers interested in learning about advances in the development of pharmaceutical agents for the treatment of infectious diseases. The scope of the book series covers a range of topics including the chemistry, pharmacology, molecular biology and biochemistry of natural and synthetic drugs employed in the treatment of infectious diseases. Reviews in this series also include research on multi drug resistance and pre-clinical / clinical findings on novel antibiotics, vaccines, antifungal agents and antitubercular agents. Frontiers in Clinical Drug Research - Anti infectives is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in the field of anti infective drug discovery and epidemiology.
The eighth volume of this series presents comprehensive reviews of interest to readers interested in the treatment of inflammatory diseases, new antiviral agents and strategies, specific antiprotozoal drugs that work against leishmania and helminths, and a study on potential agents against American foulbrood in honey bees.
The eighth volume of this series presents comprehensive reviews of interest to readers interested in the treatment of inflammatory diseases, new antiviral agents and strategies, specific antiprotozoal drugs that work against leishmania and helminths, and a study on potential agents against American foulbrood in honey bees.
The 7 reviews included in this volume are:
- Monoclonal antibodies as therapeutic agents for inflammatory diseases
- Pharmacotherapy of emerging antiviral agents
- Antiviral activity of vitamin D and COVID-19: current understanding
- Anti-infectives to combat leishmaniasis
- Anthelmintic drug discovery: current situation and future perspectives
- Therapeutic targets for emerging Zika virus infection and vaccines in clinical trials
- Agro-industrial waste: new source of raw material for the control of American foulbrood in honey bees
Table of Contents
Chapter 1 Monoclonal Antibodies As Therapeutic Agents For Inflammatory Diseases- Introduction
- Monoclonal Antibodies
- Structure And Properties Of Antibodies
- Relevance And Applications Of Monoclonal Antibodies
- Monoclonal Antibodies Therapeutics Market
- Inflammation Overview
- G-Protein-Coupled Receptors
- Adhesion Receptors
- Pattern Recognition Receptors
- Fc-Receptors
- Cytokine Receptors
- Monoclonal Antibody-Based Therapies For The Treatment Of Inflammation
- Interleukin-8 And Interleukin-6
- Anti-Interleukin-8 And Anti-Interleukin-6 Mabs
- Role Of Anti- Il-6 Mabs In The Severe Acute Respiratory Syndrome-2
- Other Recently Approved Monoclonal Antibodies For Inflammatory Diseases
- Risankizumab-Rzaa
- Polatuzumab Vedotin-Piiq
- Brolucizumab-Dbll
- Teprotumumab-Trbw
- Satralizumab-Mwge
- Concluding Remarks
- Consent For Publication
- Conflict Of Interest
- Acknowledgements
- References
Chapter 2 Pharmacotherapy Of Emerging Antiviral Agents
- Gaurav M Doshi, Hemen S Ved, Ami P Thakkar, Nirav Y. Bhatia And Prachi M Pimple1
- Introduction
- Existing Antiviral Classification
- 5-Substituted 2′-Deoxyuridine Analogs
- Nucleoside Analogs
- Pyrophosphate Analogs
- Nucleoside Reverse Transcriptase Inhibitors
- Nonnucleoside Reverse Transcriptase Inhibitors
- Entry Inhibitors
- Acyclic Guanosine Analogs
- Acyclic Nucleoside Phosphonate Analogs
- Hcv Ns5A/Ns5B Inhibitors
- Hiv And Hcv Ns3/4A Protease Inhibitors
- Integrase Inhibitors
- Newer Antiviral Agents
- For Hsv Infections
- Brincidofovir
- Ub-621
- Amenamevir (Asp2151)
- Pritelivir
- For Hpv Infections
- Gx-17, Nt-17
- Teslexivir, Ap611074, Bta074
- Abi 1968; Hti-1968
- For Vzv Infections
- Fv-100, Valnivudine
- For Rsv Infections
- Medi8897/ Nirsevimab:
- Pc786
- Jnj-53718678, Nj-678; Jnj-8678, Rilematovir
- For Hiv Infections
- Budigalimab
- Gsk3640254
- Ub-421
- For Hcv Infections
- Uprifosbuvir
- For Hbv Infections
- Selgantolimod
- Jnj-73763989
- Vir-2218
- Conclusion
- Abbreviations
- Consent For Publication
- Conflict Of Interest
- Acknowledgements
- References
Chapter 3 Antiviral Activity Of Vitamin D And Covid 19: Current Understanding
- Mahmood A. Al-Azzawi And Moustafa A. Sakr
- Introduction
- Vitamin D And Microbial Infection: Insight On Mechanisms Basedinhibition
- The Role Of Vitamin D In Covid-19 Disease
- Clinical And Epidemiological Findings Concerning Covid-19
- The Role Of Vitamin D In Covid-19 Infections And Outcomes: An Insight On Current Studies
- Recommendations
- Conclusion And Perspectives
- Consent For Publication
- Conflict Of Interest
- Acknowledgements
- References
Chapter 4 Anti-Infectives To Combat Leishmaniasis
- Shalini Roy, Anindita Ukil And Pijush K. Das
- Introduction
- Leishmaniasis
- Causative Parasite And The Vector
- Life Cycle
- Mode Of Transmission
- Disease Manifestations
- Current Treatment Options
- Evation Of Host Defense
- Host Resistance Factor
- Drugs For Treatment Of Leishmaniasis
- Antimonials
- Species-Specific Diversity
- Clinical Resistance
- Advantages And Disadvantages
- Amphotericin B
- Species-Specific Diversity
- Clinical Resistance
- Advantages And Disadvantages
- Ambisome
- Miltefosine As Third-Line Treatment
- Clinical Resistance
- Advantages And Disadvantages
- Paromomycin (Aminosidine)
- Species-Specific Diversity
- Clinical Resistance
- Investigational Drugs
- Azoles
- Species Variation
- Clinical Resistance
- Nitroimidazole Compound
- Fexinidazole
- Pa-824
- Sitamaquine
- Nucleoside Analogues
- Quinoline Derivatives
- Aminoquinaldine Compounds
- Naphthoquinones
- Doxorubicin
- Other Investigational Agents
- Nano-Amphotericin B
- Carbon Nanotubes
- Oral Lipid-Based Formulation Of Amphotericin B
- Other Amphotericin B Preparations
- Present Scenario Pertaining To The Use Of Therapeutics
- Future Agenda For Better Remedial Measures
- New Targets, New Drugs
- Cost And Distribution Of Drugs
- Emerging Roles Of Immunomodulators
- Scopes For Combinatorial Therapies
- Vaccines: A Potential Therapeutic Angle
- Scopes For Advancement Of Techniques To Explore New Leads And Diagnostics
- Conclusion
- Consent For Publication
- Conflict Of Interest
- Acknowledgements
- References
Chapter 5 Anthelmintic Drug Discovery: Current Situation And Future Perspectives
- María Gabriela Blanco María José De Rosa And Diego Rayes
- Introduction To Parasitic Nematodes
- Helminths: Phylum Nematoda
- Overview Of Nematode Infections
- Intestinal Infections
- Tissue Infections
- Parasitic Nematodes
- Intestinal Nematodes
- Ascariasis
- Trichuriasis
- Hookworm Infections
- Strongyloidiasis
- Enterobiasis
- Tissue Nematodes
- Filariasis
- Lymphatic Filariasis (Lf)
- Subcutaneous Filariasis
- Onchocerciasis
- Loiasis
- Trichinellosis
- Anthelmintic Drugs
- Benzimidazoles
- Imidazothiazoles And Tetrahydropyrimidines
- Macrocyclic Lactones
- Piperazine Derivatives
- Promising Drugs
- Tribendimidine
- Cyclooctadepsides
- Pyrimidine Derivative
- Nematode Infection Treatment
- Intestinal Infections
- Ascariasis
- Trichuriasis
- Hookworm Infections
- Strongyloidiasis
- Enterobiasis
- Tissue Infections
- Lymphatic Filariasis (Lf)
- Subcutaneous Filariasis
- Onchocerciasis
- Loiasis
- Trichinellosis
- Who And Mass Drug Administration
- The Need To Develop New Anthelmintic Control Strategies
- C. Elegans: A Nematode Model For Drug Discovery
- Concluding Remarks
- Acknowledgements
- Consent For Publication
- Conflict Of Interest
- Author Contributions
- List Of Abbreviations
- References
Chapter 6 Therapeutic Targets For Emerging Zika Virus Infection And Vaccines In Clinical Trials
- Deepthi Ramesh, Balaji Gowrivel Vijayakumar And Tharanikkarasu Kannan Zika Virus Discovery And Epidemiology
- Zika Virus Genome Structure And Life Cycle
- Virion Structure
- Viral Entry And Replication Cycle In The Host
- Molecular Pathogenesis
- Zika Virus Transmission
- Clinical Manifestations
- Diagnostics
- Prevention And Control Of Zikv Transmission
- Viral Therapeutics
- Zika Virus Structural Proteins As Drug Targets
- Zika Virus Nonstructural Proteins As Drug Targets
- Host Cell Proteins As Drug Targets
- Drug Discovery Initiatives For Treating Zika Virus Infection
- Nucleoside And Nucleotide Analogs
- Non-Nucleoside Rna Polymerase Inhibitor
- Protease Inhibitors
- Fusion Inhibitors
- Inhibitors Of Host Nucleoside Biosynthesis
- Zika Virus Vaccine
- Summary And Concluding Remarks
- Consent For Publication
- Conflict Of Interest
- Acknowledgement
- References
Chapter 7 Agro-Industrial Waste: New Source Of Raw Material For The Control Of American Foulbrood In Honey Bees
- Pablo Giménez-Martínez1,2, Cristina Ramírez3, Azucena Iglesias1,2, Florencia Fangio4, Sandra Churio, Matias Maggi And Sandra Fuselli
- Introduction
- American Foulbrood
- Characteristics Of The Disease
- Paenibacillus Larvae, The Causal Agent
- Pathogenesis And Symptoms
- Disease Control
- Conventional Chemotherapy Treatment
- Alternative Chemotherapy Treatment
- Bioactive Compounds As An Alternative To Synthetic Antibiotics
Author
- Atta-ur-Rahman
